FluoGuide A/S (SE:FLUO)

:FLUO

FLUO

FluoGuide A/S

RESEARCH TOOLSreports

Want to see SE:FLUO full AI Analyst Report?

FluoGuide A/S (FLUO) Price & Analysis

1 Followers

FLUO Stock Chart & Stats

kr36.00

-kr1.70(-3.82%)

At close: Mar 06 4:00 PM EST

kr36.00

-kr1.70(-3.82%)

Day’s Range― - ―

52-Week Rangekr28.00 - kr47.60

Previous CloseN/A

Volume5.01K

Average Volume (3M)8.21K

Market Cap

kr678.50M

Enterprise Valuekr371.74M

Total Cash (Recent Filing)kr78.84M

Total Debt (Recent Filing)kr28.30M

Price to Earnings (P/E)―

Beta0.29

Next Earnings

May 27, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-2.82

Shares Outstanding16,349,314

10 Day Avg. Volume11,579

30 Day Avg. Volume8,206

Financial Highlights & Ratios

PEG Ratio-0.29

Price to Book (P/B)6.10

Price to Sales (P/S)0.00

P/FCF Ratio-8.79

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.98

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet Equity BufferA materially larger equity base provides a durable capital buffer to absorb ongoing R&D and operating losses, extending the company's runway versus a thinner capital structure. This reduces near-term solvency risk and gives management time to advance commercialization and clinical milestones.

Focused Clinical Product StrategyA targeted product set focused on intraoperative fluorescence imaging addresses structural demand in oncology surgery. Specialised imaging agents tied to surgical workflows create adoption pathways and intellectual property potential, supporting long-term differentiated market positioning if clinical validation succeeds.

Positive Gross Profit In Revenue YearsConsistent positive gross profit in years with sales indicates underlying product economics can cover variable costs. If the company can control operating expenses and scale clinical/commercial activities, positive unit economics support a credible path to sustainable margins over time.

Bears Say

Collapsed RevenueThe sharp, sustained decline to effectively zero revenue demonstrates weak commercial traction or recognition timing risks. Without stable sales, the company cannot validate market adoption, making long-term cash generation and commercialization highly uncertain absent new revenue channels or partnerships.

Persistent High Cash BurnLarge, recurring negative operating cash flow and negative free cash flow mean the business is structurally reliant on external financing. This creates ongoing dilution and execution risk, and reduces flexibility to invest in commercialization unless burn meaningfully declines or revenue ramps sustainably.

Rising LeverageA rapid increase in debt raises fixed obligations and refinancing risk as the company remains pre-commercial. Higher leverage narrows financial flexibility, can increase interest costs, and heightens vulnerability if revenue generation continues to lag, pressuring long-term solvency if growth is delayed.

FLUO FAQ

What was FluoGuide A/S’s price range in the past 12 months?

FluoGuide A/S lowest stock price was kr28.00 and its highest was kr47.60 in the past 12 months.

What is FluoGuide A/S’s market cap?

FluoGuide A/S’s market cap is kr678.50M.

When is FluoGuide A/S’s upcoming earnings report date?

FluoGuide A/S’s upcoming earnings report date is May 27, 2026 which is tomorrow.

How were FluoGuide A/S’s earnings last quarter?

FluoGuide A/S released its earnings results on Feb 25, 2026. The company reported -kr1.278 earnings per share for the quarter, missing the consensus estimate of N/A by -kr1.278.

Is FluoGuide A/S overvalued?

According to Wall Street analysts FluoGuide A/S’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does FluoGuide A/S pay dividends?

FluoGuide A/S does not currently pay dividends.

What is FluoGuide A/S’s EPS estimate?

FluoGuide A/S’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does FluoGuide A/S have?

FluoGuide A/S has 16,349,314 shares outstanding.

What happened to FluoGuide A/S’s price movement after its last earnings report?

FluoGuide A/S reported an EPS of -kr1.278 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of FluoGuide A/S?

Currently, no hedge funds are holding shares in SE:FLUO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

FluoGuide A/S

FluoGuide A/S, a life science company, engages in the development and sale of surgical solutions in Denmark. Its lead product candidate is FG001, which is in Phase I/II for the treatment of high-grade glioma, as well as Phase II clinical trial for the treatment of lung cancer. The company also develops FG002, which is in preclinical stage that allows surgeons to differentiate cancer from normal tissue during surgery through a novel uPAR-targeted luminescent technology. FluoGuide A/S has an agreement with Linköping University Hospital for the development of FG001 that is in the Phase I/II clinical trial for surgical removal of brain cancer; and a collaboration with Copenhagen University Hospital. The company was incorporated in 2018 and is headquartered in Copenhagen, Denmark.